Published in J Steroid Biochem Mol Biol on September 01, 1994
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol (2009) 6.68
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol (2010) 5.86
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res (2011) 4.65
Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res (2009) 3.61
Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol (2008) 3.56
Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer (2004) 3.32
Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol (2009) 3.13
A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell (2013) 2.94
Common gene rearrangements in prostate cancer. J Clin Oncol (2011) 2.89
Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res (2011) 2.23
CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol (2010) 1.70
The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol (2011) 1.55
CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br J Cancer (2009) 1.33
An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer (2010) 1.32
Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene (2014) 1.31
Molecular pathways: Inhibiting steroid biosynthesis in prostate cancer. Clin Cancer Res (2013) 1.26
Mechanisms of androgen receptor activation in castration-resistant prostate cancer. Endocrinology (2013) 1.12
Novel therapeutic approaches for the treatment of castration-resistant prostate cancer. J Steroid Biochem Mol Biol (2013) 0.99
New players for advanced prostate cancer and the rationalisation of insulin-sensitising medication. Int J Cell Biol (2013) 0.98
Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men. Cancer Chemother Pharmacol (2012) 0.94
Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment. Oncotarget (2015) 0.92
Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. Oncologist (2011) 0.90
Progress of molecular targeted therapies for prostate cancers. Biochim Biophys Acta (2011) 0.89
Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy. Ther Adv Urol (2015) 0.88
The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer. Chem Biol Interact (2014) 0.88
Cell mates: paracrine and stromal targets for prostate cancer therapy. Nat Rev Urol (2013) 0.87
Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clin Cancer Res (2014) 0.87
Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol (2012) 0.86
Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer. Clin Med Insights Urol (2013) 0.85
Abiraterone in the treatment of metastatic castration-resistant prostate cancer. Cancer Manag Res (2014) 0.83
Effects of aromatase inhibition versus gonadectomy on hippocampal complex amyloid pathology in triple transgenic mice. Neurobiol Dis (2011) 0.82
ETS rearrangements in prostate cancer. Asian J Androl (2012) 0.82
Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer. Maturitas (2010) 0.82
New developments in the treatment of castration resistant prostate cancer. Asian J Androl (2014) 0.81
Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. Drug Des Devel Ther (2012) 0.81
Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant. Cancer Biol Ther (2012) 0.79
Association of early PSA decline and time to PSA progression in abiraterone acetate-treated metastatic castration-resistant prostate cancer; a post-hoc analysis of Japanese phase 2 trials. BMC Urol (2016) 0.79
Steroidogenic factor 1 promotes aggressive growth of castration-resistant prostate cancer cells by stimulating steroid synthesis and cell proliferation. Endocrinology (2013) 0.79
New therapeutics to treat castrate-resistant prostate cancer. ScientificWorldJournal (2013) 0.79
Revisiting the role of antiandrogen strategies in ovarian cancer. Oncologist (2011) 0.77
Novel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate Cancer. Drug Discov Today Ther Strateg (2010) 0.76
Abiraterone acetate. Drugs R D (2010) 0.75
Resisting resistance: Establishing new treatment options for CRPC patients. Cancer Biol Ther (2016) 0.75
Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts. Clin Cancer Res (2016) 0.75
Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancer. Cancer Sci (2014) 0.75
AR Signaling in Breast Cancer. Cancers (Basel) (2017) 0.75
Rhabdomyolysis-induced acute kidney injury in a cancer patient exposed to denosumab and abiraterone: a case report. BMC Nephrol (2015) 0.75
Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy. Prostate Int (2014) 0.75
Alternative strategies for the treatment of classical congenital adrenal hyperplasia: pitfalls and promises. Int J Pediatr Endocrinol (2010) 0.75
Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer. J Clin Invest (2017) 0.75
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet (2005) 11.05
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet (2011) 10.62
Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst (2003) 6.20
Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet (1998) 5.35
A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol (1995) 3.79
Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem (1995) 3.72
Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer (2004) 3.32
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol (1999) 2.32
The synthesis of oligoribonucleotides. IV. Preparation of dinucleoside phosphates from 2',5'-protected ribonucleoside derivatives. Tetrahedron (1968) 2.31
Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer (2011) 2.20
Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res (1995) 2.05
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet (2015) 2.05
Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res (1987) 2.03
Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. J Steroid Biochem Mol Biol (1997) 1.94
Breast-cancer osteolysis, bone metastases, and anti-osteolytic effect of aspirin. Lancet (1976) 1.92
Best Practice No 176: Updated recommendations for HER2 testing in the UK. J Clin Pathol (2004) 1.90
A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer (1989) 1.78
Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res (1992) 1.71
Comparison of new immunohistochemical assay for oestrogen receptor in paraffin wax embedded breast carcinoma tissue with quantitative enzyme immunoassay. J Clin Pathol (1994) 1.62
Isolation and identification of products from alkylation of nucleic acids: ethyl- and isopropyl-purines. Biochem J (1975) 1.62
Reaction products from N-methyl-N-nitrosourea and deoxyribonucleic acid containing thymidine residues. Synthesis and identification of a new methylation product, O4-methylthymidine. Biochem J (1973) 1.50
Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration. Lancet (1994) 1.49
Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques. Br J Cancer (2005) 1.48
Response to specific anti-oestrogen (ICI182780) in tamoxifen-resistant breast cancer. Lancet (1995) 1.47
Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer (2000) 1.45
The alkylation of 2'-deoxyguanosine and of thymidine with diazoalkanes. Some observations on o-alkylation. Biochem J (1973) 1.43
Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women. Eur J Cancer (2010) 1.43
Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res (1994) 1.43
Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. Lancet Oncol (2013) 1.43
Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res (1993) 1.42
Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. J Clin Endocrinol Metab (1993) 1.41
Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial. Fertil Steril (1995) 1.41
Recommendations for HER2 testing in the UK. J Clin Pathol (2000) 1.41
Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4'-tetramethoxystilbene. Br J Cancer (2004) 1.40
Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer (1996) 1.40
Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol (2009) 1.40
The synthesis of oligoribonucleotides. II. Methoxymethylidene derivatives of ribonucleosides and 5'-ribonucleotides. Tetrahedron (1967) 1.39
Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat (1998) 1.39
Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. Lancet (1980) 1.38
Chemical trapping of a reactive metabolite. The metabolism of the AZO-mustard 2'-carboxy-4-di-(2-chloroethyl)amino-2-methylazobenzene. Biochem Pharmacol (1972) 1.38
A new treatment for endometriosis. Lancet (1989) 1.38
4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet (1984) 1.35
Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer. Eur J Cancer Clin Oncol (1984) 1.34
A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome. Nat Genet (1992) 1.34
Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin Cancer Res (1999) 1.32
In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res (1998) 1.31
Preoperative chemotherapy induces apoptosis in early breast cancer. Lancet (1997) 1.31
Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen. J Steroid Biochem Mol Biol (2003) 1.31
Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann Oncol (2002) 1.30
Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide. Biochem Pharmacol (1974) 1.29
A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. Br J Cancer (1997) 1.26
Plasma disposition of vitamin K1 in relation to anticoagulant poisoning. Br J Clin Pharmacol (1984) 1.26
Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance. Oncogene (2010) 1.25
A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey. Br J Cancer (1997) 1.25
Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. J Clin Endocrinol Metab (1982) 1.25
Aminoglutethimide dose and hormone suppression in advanced breast cancer. Eur J Cancer Clin Oncol (1983) 1.25
Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol (2006) 1.23
Alkylation by propylene oxide of deoxyribonucleic acid, adenine, guanosine and deoxyguanylic acid. Biochem J (1972) 1.23
Tumour inhibitory triazenes: structural requirements for an active metabolite. Biochem Pharmacol (1976) 1.22
HER2 testing in the UK: further update to recommendations. J Clin Pathol (2008) 1.22
Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer. Br J Cancer (2003) 1.18
Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res (1997) 1.17
Immunoreactive calcitonin production by human lung carcinoma cells in culture. Br J Cancer (1975) 1.16
Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin Cancer Res (2000) 1.16
Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis. J Med Chem (1995) 1.15
Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer. Br J Cancer (1983) 1.15
The biology of neoadjuvant chemotherapy for breast cancer. Endocr Relat Cancer (2002) 1.14
High dose melphalan and non-cryopreserved autologous bone marrow treatment of malignant melanoma and neuroblastoma. Exp Hematol (1979) 1.13
Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer. Breast Cancer Res Treat (2003) 1.13
Identification of an exon 3 deletion splice variant androgen receptor mRNA in human breast cancer. Int J Cancer (1997) 1.12
ARIMIDEX: a new oral, once-a-day aromatase inhibitor. J Steroid Biochem Mol Biol (1995) 1.11
Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee. Cancer Chemother Pharmacol (1998) 1.10
Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. Endocr Relat Cancer (2011) 1.10
The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin. Br J Clin Pharmacol (1988) 1.07
Human breast tumour-induced osteolysis and prostaglandins. Prostaglandins (1976) 1.07
3- and 4-pyridylalkyl adamantanecarboxylates: inhibitors of human cytochrome P450(17 alpha) (17 alpha-hydroxylase/C17,20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer. J Med Chem (1996) 1.07
Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res (1997) 1.07
Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen. Eur J Cancer (1994) 1.06
Cytological evaluation of biological prognostic markers from primary breast carcinomas. Breast Cancer Res Treat (1997) 1.06
Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res (1993) 1.06
High incidence of HER-2 positivity in inflammatory breast cancer. Breast (2004) 1.05
Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res (2001) 1.05
The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling. Endocr Relat Cancer (2005) 1.05
Abnormal vitamin K metabolism in the presence of normal clotting factor activity in factory workers exposed to 4-hydroxycoumarins. Br J Clin Pharmacol (1986) 1.04
Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report. Cancer Res (1986) 1.04
Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer. Br J Cancer (2012) 1.04
cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice. Clin Cancer Res (1997) 1.03
Towards a molecular basis for tamoxifen resistance in breast cancer. Ann Oncol (1992) 1.03
Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br J Cancer (1996) 1.02